Celesio AG / Key word(s): Disposal
25.10.2012 15:43
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Celesio sells DocMorris to Zur Rose AG
Stuttgart, 25 October 2012. Celesio sells its subsidiary and mail-order
pharmacy DocMorris N.V., Heerlen, as well as the DocMorris trademark to the
Swiss Zur Rose AG. The purchase price amounts to 25 million euro; this
entails additional impairment losses amounting to approximately 30 million
euro. These will already be considered in the interim report as of 30
September 2012. Celesio confirms its expectations for the 2012 fiscal year
and assumes that adjusted EBITDA for 2012 will at least match the 2011
level with a minimum of 550 million euro.
Contacts
Investor Relations:
Dr Sabine Göttgens, Celesio AG, +49 (0)711.5001-1188
investor@celesio.com
Markus Georgi, Celesio AG, +49 (0)711.5001-1208
investor@celesio.com
Media:
Dr Jens Schreiber, Celesio AG, +49 (0)711.5001-380
media@celesio.com
Rainer Berghausen, Celesio AG, +49 (0)711.5001-549
media@celesio.com
25.10.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Celesio AG
Neckartalstr. 155
70376 Stuttgart
Germany
Phone: +49 (0)711 5001-735
Fax: +49 (0)711 5001-740
E-mail: investor@celesio.com
Internet: www.celesio.com
ISIN: DE000CLS1001
WKN: CLS100
Indices: MDAX
Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime
Standard), München, Stuttgart; Freiverkehr in Hamburg,
Hannover; Terminbörse EUREX
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Celesio AG: Celesio sells DocMorris to Zur Rose AG
| Source: EQS Group AG